Pulmonology · Neonatal Respiratory Distress Syndrome
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Hyaline membrane disease is caused by a surfactant deficiency leading to alveolar collapse and atelectasis in premature infants.
The most significant risk factor for development is prematurity, specifically gestational age less than 32 weeks.
Chest X-ray classically demonstrates diffuse bilateral ground-glass opacities and air bronchograms.
Antenatal prevention involves the administration of corticosteroids (betamethasone or dexamethasone) to the mother to accelerate fetal lung maturation.
Postnatal treatment requires exogenous surfactant replacement therapy administered via an endotracheal tube.
The pathophysiology involves increased surface tension within the alveoli, resulting in decreased lung compliance and ventilation-perfusion mismatch.
Prolonged high-concentration oxygen therapy in these infants increases the risk of bronchopulmonary dysplasia and retinopathy of prematurity.
Vignette unlocked
A 28-week gestation male infant is delivered via emergency cesarean section due to placental abruption. Shortly after birth, the infant develops tachypnea, nasal flaring, intercostal retractions, and an expiratory grunt. Arterial blood gas reveals hypoxemia and hypercapnia. A chest radiograph shows diffuse bilateral ground-glass opacities with air bronchograms.
What is the most likely diagnosis?
Hyaline membrane disease (Neonatal Respiratory Distress Syndrome)
The clinical presentation of respiratory distress in a premature infant combined with the classic radiographic findings of ground-glass opacities and air bronchograms is diagnostic for hyaline membrane disease, as described in Bet 3.
Full handout
High yield triage
Etiology / Epidemiology
Caused by surfactant deficiency in preterm infants (risk rises markedly <32 weeks). Primary risk factor is gestational age.
Clinical Manifestations
Presents with respiratory distress syndrome, nasal flaring, and expiratory grunting shortly after birth.
Diagnosis
Diagnosis via CXR showing ground-glass opacities and air bronchograms.
Treatment
Management includes exogenous surfactant and nasal CPAP; avoid excessive oxygen.
Prognosis
Risk of bronchopulmonary dysplasia; survival is high with antenatal corticosteroids.
Full handout
Epidemiology & Etiology
Primarily affects premature infants due to structural and functional immaturity of the lungs. Incidence is inversely proportional to gestational age and birth weight. Maternal diabetes is a significant risk factor due to fetal hyperinsulinemia delaying surfactant production.
Pertinent Anatomy
The lungs lack mature type II pneumocytes, which are responsible for the synthesis and secretion of pulmonary surfactant. This deficiency leads to high surface tension within the alveoli, causing widespread atelectasis.
Pathophysiology
Surfactant deficiency causes alveolar collapse, leading to ventilation-perfusion mismatch and severe hypoxemia. The resulting injury to the alveolar epithelium leads to the formation of hyaline membranes composed of fibrin and necrotic debris. This creates a vicious cycle of atelectasis, pulmonary edema, and increased work of breathing.
Clinical Manifestations
Symptoms typically begin within minutes of birth, including tachypnea, intercostal retractions, and cyanosis. The classic expiratory grunting is a compensatory mechanism to maintain positive end-expiratory pressure. Apnea and bradycardia are late-stage signs of impending respiratory failure.
Diagnosis
The CXR is the diagnostic gold standard, revealing diffuse ground-glass opacities and prominent air bronchograms. Arterial blood gas typically demonstrates respiratory acidosis and hypoxemia. Diagnosis is clinical in the setting of a premature infant with progressive respiratory distress.
Treatment
Initial management involves nasal CPAP to prevent alveolar collapse. Exogenous surfactant (e.g., beractant) is administered via endotracheal tube to reduce surface tension. High concentrations of oxygen should be avoided to prevent retinopathy of prematurity and bronchopulmonary dysplasia.
Prognosis
Most infants improve after 3-5 days of treatment. Long-term complications include bronchopulmonary dysplasia and neurodevelopmental impairment. Antenatal corticosteroids (betamethasone) administered to the mother significantly reduce disease severity.
Differential Diagnosis
Transient tachypnea of the newborn: usually term infants, resolves within 24 hours
Group B Strep pneumonia: indistinguishable on CXR, requires antibiotics
Meconium aspiration syndrome: associated with post-term infants and green amniotic fluid
Persistent pulmonary hypertension: characterized by severe hypoxemia out of proportion to lung findings
Congenital heart disease: cyanosis that does not improve with supplemental oxygen